BURLINGTON, Mass. & NEW YORK–(BUSINESS WIRE)–Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.
During the event, Butterfly’s executive management team will present the Company’s product, software and services portfolio within the point-of-care ultrasound landscape, as well as its strategic initiatives, technology roadmap, and overarching vision. The agenda will include live demonstrations of products, including the newly released, next-generation Butterfly iQ3™.
Speakers will include:
President, Chief Executive Officer & Chairman Joseph DeVivo
Chief Financial & Operations Officer, Heather Getz
Chief Medical Officer, John Martin, MD
Chief Technology Officer, Andrei Stoica, PhD
Chief Strategy Officer, Darius Shahida
Senior Vice President of Home Care, Paula LeClair
Senior Director of Global Health, Sachita Shah, MD
Butterfly will also be joined by strategic partners introducing AI tools and novel products that are in co-development.
Attendance at the event will be reserved for analysts and institutional investors. To inquire about attendance at the event, please reach out to [email protected] and [email protected].
A copy of the presentation materials and replay of the event will be available following the event on Butterfly’s Events & Presentations page on the investor relations website.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world’s first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
Contacts
Butterfly Media:
Liz Learned
Head of Corporate Communications, Butterfly
[email protected]
Butterfly Investors:
Heather Getz
Chief Financial and Operations Officers, Butterfly
[email protected]
or
Neal Nagarajan
IR Agency Representative, Sloane & Company
(301) 273-5662
[email protected]